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G
OOD CLASSIFICATIONS OF DISEASES IN HUMANS
have contributed greatly to medical progress
by improving communication, allowing com-
parisons, and supporting large scale epidemiologic
and therapeutic studies. Well known examples are the
classification of malignant tumours, the Diagnostic
and Statistical Manual of mental diseases, or the
functional classification of exercise tolerance in heart
disease prepared by the New York Heart Association,
not to mention large works such as the classification
of diseases by the World Health Organisation, of
which the classification of pulmonary hypertension as
a rare, so-called orphan, disease is part.
The advent of targeted specific treatment for
pulmonary hypertension in the new millennium
made it obvious that a new scheme was needed for
the classification of aetiologically different forms
so as to reflect their therapeutic accessibility. The
revised classification proposed by groups meeting in
Evian in 1998,1 and Venice in 2003,2 achieved this
aim successfully, with many clinical studies based
on, and a number of therapeutic substances licensed
according to, the new classification.
How was this done? The crucial achievement of
the classification has been the fact that a number
of diseases are grouped together as ‘‘pulmonary arterial
hypertension’’, unifying those forms where the
pulmonary vascular disease process takes place in
the arterial side of the pulmonary arterial tree and,
in most cases, responds to the modern options for
treatment provided by agents such as prostanoids,
antagonists of endothelin receptors, and inhibitor of
the phosphodiesterase Type V. The new classifica-
tion also implied similar severity and prognosis in
the respective groups of patients, and was used
avidly in almost all major therapeutic trials. For
example, the idiopathic variant, the old ‘‘primary’’
pulmonary hypertension, and the form associated with
congenital cardiac disease, previously considered a
‘‘secondary’’ variant, are probably quite different
diseases, despite similarities in features such as the
histological aspects. Patients from both of these
subgroups, nonetheless, profited from this classifi-
cation in becoming officially treatable as soon
as new substances were licensed for ‘‘pulmonary
arterial hypertension’’.
The success of this general classification is in
contrast, however, with the still incoherent sub-
classification of pulmonary arterial hypertension
seen in the setting of congenitally malformed
hearts, which lacks insight despite notable attempts
at improvement,3 thus prompting the justified and
necessary initiative by van Albada and Berger4 to
improve the nosology. This is not at all an academic
exercise, but a very necessary task in view of the
increasing numbers of grown-up patients with
congenitally malformed hearts and pulmonary
arterial hypertension, who will come to outnumber
by far those patients with more ‘‘classical’’ variants
of the disease.5 The difficulties with restructuring
the classification, however, soon become apparent.
Any modification should be simple enough to allow
grouping of sufficient numbers of patients to show
efficacy of therapies, but also to satisfy their
complicated anatomy and physiology.
Van Albada and Berger4 must be commended for
their clear analysis of the problems with the current
Correspondence to: Ingram Schulze-Neick, National UK Service for Pulmonary
Hypertension in Children, Cardiac Unit, Great Ormond Street Hospital,
London WC1N 3JH, United Kingdom. Tel: 144 (0)207 405 9200 ext 1005/
1007/6707; Fax: 144 (0)207 905 2321; E-mail: neicki@gosh.nhs.uk
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S1047951107001850
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 18:03:08, subject to the Cambridge Core terms of use, available at
classification (See Table 1) by introducing a much
needed view, which is the recognition of the
haemodynamic burden to the lung. Being led by this
variable, they recognise several risk factors for
developing pulmonary arterial hypertension, rephrased
by us as:
> Pre- or post-tricuspid location of the shunt, in
other words with or without additional stress of
pressure on the pulmonary arterial system
> Increased flow of blood to the lungs
> Non-restrictive nature of shunting, either in the
absence of surgery, or because of a residual lesion
despite surgery
> The timing of surgical correction
> The presence of intra- and extracardiac abnorm-
alities
> Individual susceptibility and genetic factors,
such as trisomy 21.
The classification proposed by van Albada and
Berger4 is certainly useful, and represents a much-
needed step in the right direction. This is because it
follows one important rule. Classifications are most
useful if they are unidimensional, in other words
organised along one easily recognisable variable to
form the index, such as age, size, gender, or severity.
The more this variable correlates with others, the
more does the classification itself assume predictive
power. A well-known and successful classification of
this type is the one proposed by the New York Heart
Association for classification of exercise tolerance.
If other variables are introduced to see what else the
classification could do, however, in this case to
improve understanding of prognosis and therapeutic
decisions, as well as to help in the adequate design
and interpretation of clinical research, then this
introduces the same potential caveats from which
the previous classifications have suffered, namely a
multidimensional approach which immediately con-
fuses the situation. The reason for this is because the
patients not only have pulmonary arterial hyperten-
sion. First and foremost they have congenitally
malformed hearts.
Neither anatomy alone, nor the haemodynamic
risk factors, clearly predict the clinical course and
prognosis of pulmonary arterial hypertension as
seen in the setting of the congenitally malformed
heart. These features vary markedly, depending on
institution and doctor providing treatment, as
well as the patient him or herself. It is necessary to
take all these aspects into account when decid-
ing optimal therapeutic strategies. Treatment of
the congenital malformation itself, by surgically
normalising or ameliorating circulation and myo-
cardial loading conditions, by corrective or palliative
surgery, or even by abstinence from surgery, creates
a range of different physiologies. Indeed, these
are the issues which interfere with the presently
existing systems for classification. This is because
the different cardiovascular physiologies that result
from corrected or uncorrected malformations may
dominate the clinical state and fate of the patient
and the response to therapy to a more important
degree than the concomitant pulmonary arterial
hypertension alone.
What are these special physiologies? This is
exactly the issue addressed by van Albada and
Berger,4 which, if we may take it a few steps further,
leads to the following view: first, there is the group
of patients that simply needs surgery as opposed
to those patients who do not yet have the typical
physiology of the Eisenmenger patient, but may
still be operable if their pulmonary vascular
resistance was minimally lower. This subgroup is
actually very important, since the pulmonary
vascular disease may progress despite successful
surgery. Then, second, there are those patients with
haemodynamics similar to idiopathic pulmonary
hypertension, namely those with insignificant shunt-
ing who have not undergone operative correction,
Table 1. Existing and suggested classifications of systemic-to-pulmonary shunts associated with pulmonary arterial hypertension
(rearranged to allow comparison).
Item/Author WHO (2003) Galie` (2006) van Albada & Berger (2007)
1. type simple, combined, complex pre-tricuspid, post-tricuspid,
combined, complex
pre-tricuspid, post-tricuspid
2. dimensions small, large restrictive, non-restrictive,
small, large
restrictive, non-restrictive
3. direction of shunt — left, right, bidirectional left, right, bidirectional
4. state of surgical repair non, partial, complete non, partial, complete non, surgical shunt, pulmonary
artery banding, complete
5. associated cardiac anomalies — — pulmonary arterial stenosis,
pulmonary venous stenosis,
left ventricular dysfunction
6. associated extracardiac anomalies absent/present absent/present absent/present
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or those who have undergone repair but still have
insignificant residual defects. There is then a third
group of patients in whom the arterial side of the
pulmonary vascular tree has developed additional
active disease as a reaction to pulmonary venous
hypertension which existed either in the past (eg.,
obstructive lesions on the left side of the heart which
with successful repair) or which is an ongoing
problem (eg., left myocardial disease with increased
enddiastolic pressures). The Eisenmenger physiology
makes up a fourth entity with its own important
pathophysiological considerations. Those with the
Fontan circulation then represent a fifth subset, with
very fragile and specific physiology. In these patients,
as with those in the other groups, the increase in
pulmonary vascular resistance leads ultimately to
failure of the circulation. Making up a sixth group,
there are those with the unusual forms of congenital
malformations that produce unilateral pulmonary
arterial hypertension, mainly because of the surgical
shunts, systemic-to-pulmonary collateral arteries,
abnormalities of the right or left pulmonary arteries.
A final seventh group is constituted by those with
increased pulmonary vascular resistance due to
general hypoplasia of the pulmonary vascular bed,
in whom pulmonary vasodilating therapy may be
explored in the absence of any other therapeutic
options. To make things more complicated, all
groups come combined not only with their own
past or ongoing risk of developing pulmonary arterial
hypertension, but also with the risk of failure of the
subpulmonary ventricle to sustain this afterload.
Thus classifying these groups according to their
underlying physiology (Table 2) shows their common
elements determining clinical course and the
potential for discussions regarding possibilities of
treatment.
The current body of evidence as condensed by van
Albada and Berger4 regarding the specific treatment of
patients with the Eisenmenger syndrome underlines
the fact that this new pathophysiologically oriented
concept for classification of pulmonary arterial
hypertension as seen in the setting of the congenitally
malformed heart, shown here with its entire spectrum,
is already implicitly used in a fruitful way. This
suggested classification, at first glance, may appear to
be out of line with the classifications proposed in
Evian and Venice, as the group with the Fontan-like
circulations does not represent patients with pulmon-
ary hypertension according to the classical and
haemodynamically simple definition of an increased
pulmonary vascular resistance of greater than 3 Wood
units per meter squared, or a mean pulmonary arterial
pressure of more than 25 millimetres of mercury.
When examined more closely, however, it becomes
apparent that this group unequivocally needs to be Ta
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part of this classification, as even a minimal increase in
pulmonary vascular resistance causes an important,
clinically relevant, problem which is very analogous
physiologically with that of patients with classical
severe pulmonary arterial hypertension and which
results in similar consequences, both in symptoms and
most likely necessary medical therapy.
It is clear that, in all classifications, there is and
must be an element of simplification, which also
implies a specific bias and some weaknesses. A
classification, nonetheless, is an instrument with
which to work. Thus, it needs to stand the test of
time. If successful, it may prove a very useful tool for
research, clinical use and ultimately the benefit of
patients. Eventually, it will find its place in official
recommendations, such as guidelines for treatment.
Modifications such as those proposed by van Albada
and Berger4 are an important and necessary part of
this comprehensive process of classification. The next
World Congress on Pulmonary Hypertension, to be
held in the United States of America in 2008, will
develop still another subclassification of pulmonary
arterial hypertension as seen in the setting of the
congenitally malformed heart, and will aim to
improve further the assessment and treatment of
these complicated patients. Hopefully those preparing
the next modification will take note both of the
suggestion of van Albada and Berger,4 and our own
comments.
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